MD Biosciences

MD Biosciences is a contract research organization (CRO) for non-clinical studies with over 30 years of experience. We support translational research, especially in the areas of neurological diseases, pain, and inflammation, and provide reliable data for drug development.

Here, we introduce the features of MD Biosciences' non-clinical studies, an example of a pathological model, and case studies.

Features of MD Biosciences' Contract Nonclinical Trial Services

Highly specialized evaluation in the area of nervous system disorders and pain

MD Biosciences provides contract services specializing in non-clinical studies of neurological, pain, and neurodegenerative diseases. Cell-basedin vitrofrom the study, using rodent and porcine models.in vivoWe offer a wide range of services, from efficacy studies of We go beyond mere behavioral evaluation and combine specialized methods such as electrophysiology, histological analysis, and biomarker analysis to evaluate the mechanism of action and efficacy of candidate compounds under development from multiple perspectives.

Translational research system with a clinical focus

The company's strength lies in translational research from the early stages of drug discovery to clinical trials. The company utilizes translational models, such as those using pigs that closely resemble human pathology, to provide data of higher clinical significance. Our well-equipped research facilities, complete with dedicated study space and analysis labs, are ready to conduct customized study programs quickly and flexibly with a lead time of 4-6 weeks.

An example of MD Biosciences' pathological model

The company operates MDB Neurosciences (mdbneuro.com), a specialized research website dedicated to neuroscience and pain, which publishes trial data and new case studies. This article focuses on the findings of this specialized site and introduces the characteristics of the company's non-clinical studies and pathological models.

Postoperative pain and nerve block models

As models for evaluation in the area of pain, we have postoperative pain models such as the Brennan's foot incision model using rodents and the pig model. These reproduce surgical tissue damage and are used to evaluate the efficacy of new analgesics.

We also offer a nerve block model that can be administered directly to the sciatic nerve to screen for local anesthetics and ion channel inhibitors. Motor and sensory evoked potentials can be measured in conjunction with behavioral changes associated with pain.

Stroke and focal and global ischemia models

For the study of stroke and ischemic diseases, we have the middle cerebral artery occlusion (MCAO) model and the whole brain ischemia model with 4 vessel occlusion (4VO). the MCAO model blocks blood flow in the middle cerebral artery and reproduces the focal brain damage seen in human stroke.

The 4VO model, on the other hand, mimics reduced cerebral blood flow during cardiac arrest or bypass surgery and is used to assess hippocampal brain damage and neurodegeneration. Through these models, nonclinical data on interventional treatments for stroke will be obtained.

MD Biosciences Non-clinical Case Studies

Evaluation of long-term analgesic effects of novel local anesthetics using a pig postoperative pain model

The efficacy of a novel local anesthetic (candidate compound for development) was evaluated in two different postoperative pain models (incision model and sciatic nerve block model) using pigs, using the von Frey method and other methods. As a result, the compound showed dose-dependent and sustained effects.

The high dose lasted approximately 120 hours in the incision model and up to 72 hours in the nerve block model, demonstrating prolonged analgesia of 3.5 days and 2.8 days, respectively, versus conventional bupivacaine hydrochloride.

Evaluation of nerve damage using evoked potentials in the MOG-induced EAE mouse model

In this study, motor and sensory evoked potentials (MEP/SEP) were measured as quantitative markers to assess nervous system damage in vivo using the MOG-induced EAE mouse model.

The results confirmed that sensory hypersensitivity occurs in asymptomatic or mild early EAE mice with a significant increase in the amplitude of sensory waves (P25) occurring 25 milliseconds after stimulation. This early hypersensitivity and asynchronous neuromotor activity has been shown to lead to complete loss of sensory and motor function in the later stages of the disease.

MD Biosciences Company Information

MD Biosciences is a biotechnology company based in the United States and Israel. As a contract research organization specializing in the fields of neurology and pain, MD Biosciences supports drug development for global pharmaceutical companies and research institutions.